Chronic Myeloid Leukemia

Chronic Myeloid Leukemia (CML)

Chronic Myeloid Leukemia (CML) is a slow-growing cancer of the bone marrow that results in the overproduction of white blood cells. It is unique because nearly all cases (approx. 95%) are caused by a specific genetic abnormality known as the Philadelphia chromosome.

When You Should Consider CML Evaluation

• Persistent fatigue or weakness.

• Drenching night sweats.

• Fullness or discomfort on the left side of the abdomen due to an enlarged spleen.

• Unexplained weight loss or mild fevers.

• Many patients have no symptoms and are diagnosed during routine blood tests.

Methods of CML Classification

• Chronic Phase: The most common stage at diagnosis (85–90% of patients) where symptoms are mild and the disease responds well to standard treatment.

• Accelerated Phase: The cancer grows faster with blast counts rising to 10–19%, and symptoms become more noticeable.

• Blast Phase (Blast Crisis): An aggressive stage with 20% or more blasts that behaves like acute leukemia and is harder to treat.

• Genetic Cause: Driven by the BCR-ABL gene, created when pieces of chromosomes 9 and 22 swap places.

How CML Treatment Is Performed

• TKI Therapy: Daily oral pills such as Imatinib (Gleevec), Dasatinib (Sprycel), or Nilotinib (Tasigna) that specifically "turn off" the BCR-ABL protein.

• Hematologic Management: Normalizing blood counts, which typically occurs within the first few weeks of treatment.

• Molecular Monitoring: Using sensitive PCR tests to measure and reduce the level of the BCR-ABL gene in the blood.

• Treatment-Free Remission (TFR): For eligible patients who maintain a deep response, stopping medication under strict medical supervision.

Pre-Procedure Preparation

• Understanding that CML is now a manageable chronic condition requiring consistent, long-term medication.

• Establishing a baseline through physical exams and medical history to check for an enlarged spleen.

• Discussing the importance of adherence to daily oral therapy to achieve a Major Molecular Response.

• Planning for frequent initial monitoring to ensure the "genetic switch" is being effectively turned off.

Tests Before CML Treatment

• Bone Marrow Biopsy: To confirm the diagnosis and determine the phase of the disease.

• FISH or PCR Testing: Highly sensitive blood tests used to detect the Philadelphia chromosome and the BCR-ABL gene.

• Complete Blood Count (CBC): To evaluate the levels of abnormal white blood cells.

• Cytogenetic Analysis: To identify the physical exchange of genetic material between chromosomes 9 and 22.

Life After CML Treatment

• Life expectancy for those in the chronic phase is now approaching that of the general population.

• The 5-year survival rate is currently over 90%, compared to roughly 20% before the year 2000.

• Patients require lifelong monitoring to ensure the disease remains in molecular remission.

• Most patients can maintain a normal lifestyle while taking daily oral targeted therapy.

Benefits of CML Treatment

• Revolutionizes the prognosis from a once-fatal disease to a manageable chronic condition.

• Specifically targets the genetic "stuck switch" (BCR-ABL) without the need for traditional intensive chemotherapy.

• Achieves Major Molecular Response, making the cancer gene nearly undetectable in the blood.

• Offers the potential for treatment-free remission in patients with deep, sustained responses.